Pharmacyclics Xcytrin NDA in late 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacyclics will submit an NDA for Xcytrin (motexafin gadolinium) for treatment of patients with brain metastases with non-small cell lung cancer, the firm announces May 9. The company claims that recent analyses of its failed Phase III SMART trial show that while overall results announced in December revealed no significant improvement in progression or survival, statistical significance was achieved in the study's North American subpopulation (1Pharmaceutical Approvals Monthly January 2006, In Brief). Pharmacyclics says it has discussed the findings with FDA. SMART (Study of Neurologic Progression with Motexafin Gadolinium & Radiation Therapy) will be presented at the American Society of Clinical Oncology meeting in Atlanta on June 3...
You may also be interested in...
Pharmacyclics Xcytrin misses endpoint
Pharmacyclics' Xcytrin (motexafin gadolinium) fails to show statistical significance for lung cancer patients with brain metastases in the 554-patient Phase III SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial, the firm reports Dec. 19. For the primary endpoint of time to neurologic progression (TNP), patients receiving whole brain radiation therapy plus Xcytrin had a median TNP of 15.4 months compared to 10 months for patients receiving radiation alone (p=0.122, hazard ratio=0.78). Pharmacyclics also notes there was "no significant difference in survival," a secondary endpoint. The firm plans to discuss the results with FDA; three trials looking at Xcytrin as a systemic therapy for relapsed lung cancer are ongoing...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.